Difference between revisions of "Non-small cell lung cancer, MET-mutated"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "Travis Osterman, DO, MS]" to "Travis Osterman, DO, MS, FAMIA]")
Line 38: Line 38:
 
|-
 
|-
 
|}
 
|}
−
====Biomarker Eligibility Criteria====
+
====Biomarker eligibility criteria====
−
*Biomarker: MET exon 14 skipping
+
*MET exon 14 skipping alterations
 
====Targeted therapy====
 
====Targeted therapy====
 
*[[Capmatinib (Tabrecta)]] 400 mg PO twice per day with or without food
 
*[[Capmatinib (Tabrecta)]] 400 mg PO twice per day with or without food
Line 48: Line 48:
 
<!-- # '''Abstract:''' Juergen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B. Garon, Harry J.M. Groen, Daniel Shao-Weng Tan, Toyoaki Hida, Maja J. De Jonge, Sergey V. Orlov, Egbert F. Smit, Pierre Jean Souquet, Johan F. Vansteenkiste, Monica Giovannini, Sylvie Le Mouhaer, Anna Robeva, Maeve Waldron-Lynch, Rebecca Suk Heist. Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study. [https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.9004 link to abstract] '''contains verified protocol''' [https://doi.org/10.1200/JCO.2019.37.15_suppl.9004 DOI] -->
 
<!-- # '''Abstract:''' Juergen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B. Garon, Harry J.M. Groen, Daniel Shao-Weng Tan, Toyoaki Hida, Maja J. De Jonge, Sergey V. Orlov, Egbert F. Smit, Pierre Jean Souquet, Johan F. Vansteenkiste, Monica Giovannini, Sylvie Le Mouhaer, Anna Robeva, Maeve Waldron-Lynch, Rebecca Suk Heist. Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study. [https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.9004 link to abstract] '''contains verified protocol''' [https://doi.org/10.1200/JCO.2019.37.15_suppl.9004 DOI] -->
 
#'''GEOMETRY mono-1:''' Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS; GEOMETRY mono-1 Investigators. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Sep 3;383(10):944-957. [https://doi.org/10.1056/nejmoa2002787 link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/32877583 PubMed] NCT02414139
 
#'''GEOMETRY mono-1:''' Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS; GEOMETRY mono-1 Investigators. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Sep 3;383(10):944-957. [https://doi.org/10.1056/nejmoa2002787 link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/32877583 PubMed] NCT02414139
 +
 +
==Tepotinib monotherapy {{#subobject:7it980|Regimen=1}}==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#top|back to top]]
 +
|}
 +
===Regimen {{#subobject:f3eig9|Variant=1}}===
 +
{| class="wikitable" style="width: 50%; text-align:center;"
 +
!style="width: 33%"|Study
 +
!style="width: 33%"|Years of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
|-
 +
|[https://doi.org/10.1056/nejmoa2004407 Paik et al. 2020 (VISION)]
 +
|2016-2020
 +
|style="background-color:#91cf61"|Phase II (RT)
 +
|-
 +
|}
 +
''Note: the FDA-recommended dose is 450 mg PO once per day; the dose here was the dose reported in VISION.''
 +
====Biomarker eligibility criteria====
 +
*MET exon 14 skipping alterations
 +
====Targeted therapy====
 +
*[[Tepotinib (Tepmetko)]] 500 mg PO once per day
 +
 +
'''Continued indefinitely'''
 +
 +
===References===
 +
#'''VISION:''' Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 Sep 3;383(10):931-943. Epub 2020 May 29. [https://doi.org/10.1056/nejmoa2004407 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/32469185 PubMed] NCT02864992
  
 
[[Category:Non-small cell lung cancer regimens]]
 
[[Category:Non-small cell lung cancer regimens]]
 
[[Category:Biomarker-specific pages]]
 
[[Category:Biomarker-specific pages]]
 
[[Category:Lung cancers]]
 
[[Category:Lung cancers]]

Revision as of 20:36, 3 February 2021

Page editor Section editor
Amit Kulkarni.jpg
 Amit Kulkarni, MBBS
University of Minnesota
Minneapolis, MN
Social-twitter-icon.png AmitKulkarniMD
TravisOsterman.jpg
 Travis Osterman, DO, MS, FAMIA
Vanderbilt University
Nashville, TN
Social-twitter-icon.png TravisOsterman
LinkedIn

Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.

3 regimens on this page
3 variants on this page


Metastatic disease

Capmatinib monotherapy

back to top

Regimen

FDA-recommended dose
Study Years of enrollment Evidence
Wolf et al. 2020 (GEOMETRY mono-1) NR Phase II (RT)

Biomarker eligibility criteria

  • MET exon 14 skipping alterations

Targeted therapy

Continued indefinitely

References

  1. GEOMETRY mono-1: Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS; GEOMETRY mono-1 Investigators. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Sep 3;383(10):944-957. link to original article contains protocol PubMed NCT02414139

Tepotinib monotherapy

back to top

Regimen

Study Years of enrollment Evidence
Paik et al. 2020 (VISION) 2016-2020 Phase II (RT)

Note: the FDA-recommended dose is 450 mg PO once per day; the dose here was the dose reported in VISION.

Biomarker eligibility criteria

  • MET exon 14 skipping alterations

Targeted therapy

Continued indefinitely

References

  1. VISION: Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 Sep 3;383(10):931-943. Epub 2020 May 29. link to original article contains verified protocol PubMed NCT02864992
Retrieved from "https://hemonc.org/w/index.php?title=Non-small_cell_lung_cancer,_MET-mutated&oldid=47061"